Primary care centers in Dalarna must improve kidney disease detection

On World Kidney Day, March 12, knowledge about kidney disease is spread globally. About one in ten Swedes has impaired kidney function without symptoms, posing major health risks if detected late. The Njurföreningen Gävle-Dala urges Region Dalarna to implement routine testing at primary care centers to catch the disease early.

Kidney disease affects more people than many realize in Sweden. Estimates suggest that around 10 percent of the population has chronic kidney disease, often without any symptoms. In Dalarna, with 286,043 inhabitants as of December 31, 2025, this could mean over 28,600 people carry a hidden kidney condition. The disease is sometimes called a 'silent disease' because it can remain symptom-free until the kidneys fail completely.

Early detection is crucial. A simple blood or urine test at a primary care center can identify the issue in its initial stages. The national care program for chronic kidney disease outlines treatments to detect more cases early and provide preventive care. Lifestyle changes and medications can slow the disease's progression, reducing the later need for dialysis or transplantation.

Despite this, systematic testing for at-risk groups—such as those with high blood pressure, diabetes, cardiovascular disease, smoking, or high BMI—is often lacking. The Njurföreningen Gävle-Dala emphasizes the need for routine tests for these groups at the region's primary care centers. To avoid unnecessary suffering and societal costs, the national program's recommendations should be followed closely.

Hans Peters, chairman of the Njurföreningen Gävle-Dala, states: 'We are happy to help in this work. Our members have plenty of experience with kidney disease and we are willing to share what we know. Let us work together to reduce the health risks that arise when a person with kidney disease goes around unaware of their condition.' The association offers support based on members' experiences to improve detection in Region Dalarna.

Relaterte artikler

A scientist in a lab analyzing a blood sample for early Alzheimer's detection, with brain scan overlays.
Bilde generert av AI

Blodprøve kan avsløre tegn på Alzheimers flere år i forveien

Rapportert av AI Bilde generert av AI

En ny studie viser at blodprøver kan avdekke tegn på Alzheimers flere år før sykdommen utvikler seg. Amerikanske forskere publiserte funnene i The Lancet.

Bare én av fem personer med høyt blodtrykk får tilstrekkelig behandling i Sverige. Helseaktører har nå blitt enige om et nytt behandlingsforløp for å forbedre oppdagelse og behandling.

Rapportert av AI

Region Dalarna plans to invest 10 million kronor to strengthen cancer care across the county. The allocation forms part of the 2027 budget proposal.

Region Dalarna has the highest sick leave in Sweden. The political majority and trade unions have therefore developed a joint action plan for a better work environment.

Rapportert av AI

Majority parties in Region Uppsala propose a budget with 592 million kronor extra for healthcare next year. Investments target primary care, elderly care, and cancer treatment. The opposition calls it an irresponsible budget, saying the funds mainly cover wage increases.

Region Dalarna's regional council has decided to allocate up to 30 million kronor extra to the care choice for child and youth psychiatry (BUP) in 2026. The investment aims to retain care providers. The opposition warns that the funds will not solve the root problems.

Rapportert av AI Faktasjekket

New data presented at the European Renal Association’s 63rd Congress in Glasgow and published in three major medical journals found that finerenone slowed kidney-function decline in adults with chronic kidney disease (CKD) without diabetes and reduced the risk of a combined kidney-and-cardiovascular outcome. A separate pooled analysis that combined results across finerenone studies also reported fewer kidney and heart-failure events in a broader CKD population.

 

 

 

Dette nettstedet bruker informasjonskapsler

Vi bruker informasjonskapsler for analyse for å forbedre nettstedet vårt. Les vår personvernerklæring for mer informasjon.
Avvis